#BEGIN_DRUGCARD DB01341

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
Not Available

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
Not Available

# Creation_Date:
2007-06-30 12:10:24 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Amiloride	Decreases the antiarrhythmic effect of quinidine
Aminophylline	The barbiturate, dihydroquinidine barbiturate, decreases the effect of aminophylline.
Amiodarone	Increases the effect of quinidine
Amitriptyline	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, amitriptyline.
Aripiprazole	Quinidine increases the effect and toxicity of aripiprazole
Atazanavir	Increased risk of cardiotoxicity and arrhythmias
Betamethasone	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone.
Cimetidine	Increases the effect of quinidine
Cisapride	Increased risk of cardiotoxicity and arrhythmias
Clomipramine	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, clomipramine.
Codeine	Quinidine decreases the analgesic effect of codeine
Cyclosporine	The barbiturate, dihydroquinidine barbiturate, increases the effect of cyclosporine.
Desipramine	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, desipramine.
Dexamethasone	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, dexamethasone.
Dextromethorphan	Quinidine increases the toxicity of dextromethorphan
Digoxin	Quinine/quinidine increases the effect of digoxin
Diltiazem	Increases the effect and toxicity of quinidine
Doxepin	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, doxepin.
Doxycycline	The anticonvulsant, dihydroquinidine barbiturate, decreases the effect of doxycycline.
Felodipine	The barbiturate, dihydroquinidine barbiturate, decreases the effect of felodipine.
Fludrocortisone	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone.
Folic Acid	Folic acid decreases the effect of anticonvulsant, dihydroquinidine barbiturate.
Gatifloxacin	Increased risk of cardiotoxicity and arrhythmias
Gefitinib	The CYP3A4 inducer, dihydroquinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib.
Grepafloxacin	Increased risk of cardiotoxicity and arrhythmias
Griseofulvin	The barbiturate, dihydroquinidine barbiturate, decreases the effect of griseofulvin.
Hydrocortisone	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone.
Imipramine	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, imipramine.
Levofloxacin	Increased risk of cardiotoxicity and arrhythmias
Levonorgestrel	Phenobarbital decreases the effect of levonorgestrel
Magnesium	The antiacid decreases the absorption of quinidine
Methadone	The barbiturate, dihydroquinidine barbiturate, decreases the effect of methadone.
Metronidazole	The barbiturate, dihydroquinidine barbiturate, decreases the effect of metronidazole.
Moxifloxacin	Increased risk of cardiotoxicity and arrhythmias
Nelfinavir	Nelfinavir increases the effect and toxicity of quindine
Nifedipine	Decreased quinidine effect, increased nifedipine effect
Nortriptyline	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, nortriptyline.
Ofloxacin	Increased risk of cardiotoxicity and arrhythmias
Oxtriphylline	The barbiturate, dihydroquinidine barbiturate, decreases the effect of oxtriphylline.
Prednisolone	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone.
Prednisone	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisone.
Procainamide	Quinidine increases the effect of procainamide
Propafenone	Quinidine increases the effect of propafenone
Quinidine	The anticonvulsant, dihydroquinidine. barbiturate, decreases the effect of quinidine.
Quinupristin	This combination presents an increased risk of toxicity
Theophylline	The barbiturate, dihydroquinidine barbiturate, decreases the effect of theophylline.
Triamcinolone	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone.

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Dihydroquinidine barbiturate

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1341

# Mechanism_Of_Action:
Barbiturates work by binding to the GABAA receptor at either the alpha or the beta sub unit.  These are binding sites that are distinct from GABA itself and also distinct from the benzodiazepine binding site. Like benzodiazepines, barbiturates potentiate the effect of GABA at this receptor.  This GABAA receptor binding decreases input resistance, depresses burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increases both the amplitude and decay time of inhibitory postsynaptic currents.  In addition to this GABA-ergic effect, barbiturates also block the AMPA receptor, a subtype of glutamate receptor. Glutamate is the principal excitatory neurotransmitter in the mammalian CNS.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
Not Available

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB01341

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
solid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2012-02-14 11:46:58 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
GABRA1

# Drug_Target_1_GenBank_ID_Gene:
X13584

# Drug_Target_1_GenBank_ID_Protein:
31631

# Drug_Target_1_GeneCard_ID:
GABRA1

# Drug_Target_1_Gene_Name:
GABRA1

# Drug_Target_1_Gene_Sequence:
>1371 bp
ATGAGGAAAAGTCCAGGTCTGTCTGACTGTCTTTGGGCCTGGATCCTCCTTCTGAGCACA
CTGACTGGAAGAAGCTATGGACAGCCGTCATTACAAGATGAACTTAAAGACAATACCACT
GTCTTCACCAGGATTTTGGACAGACTCCTAGATGGTTATGACAATCGCCTGAGACCAGGA
TTGGGAGAGCGTGTAACCGAAGTGAAGACTGATATCTTCGTCACCAGTTTCGGACCCGTT
TCAGACCATGATATGGAATATACAATAGATGTATTTTTCCGTCAAAGCTGGAAGGATGAA
AGGTTAAAATTTAAAGGACCTATGACAGTCCTCCGGTTAAATAACCTAATGGCAAGTAAA
ATCTGGACTCCGGACACATTTTTCCACAATGGAAAGAAGTCAGTGGCCCACAACATGACC
ATGCCCAACAAACTCCTGCGGATCACAGAGGATGGCACCTTGCTGTACACCATGAGGCTG
ACAGTGAGAGCTGAATGTCCGATGCATTTGGAGGACTTCCCTATGGATGCCCATGCTTGC
CCACTAAAATTTGGAAGTTATGCTTATACAAGAGCAGAAGTTGTTTATGAATGGACCAGA
GAGCCAGCACGCTCAGTGGTTGTAGCAGAAGATGGATCACGTCTAAACCAGTATGACCTT
CTTGGACAAACAGTAGACTCTGGAATTGTCCAGTCAAGTACAGGAGAATATGTTGTTATG
ACCACTCATTTCCACTTGAAGAGAAAGATTGGCTACTTTGTTATTCAAACATACCTGCCA
TGCATAATGACAGTGATTCTCTCACAAGTCTCCTTCTGGCTCAACAGAGAGTCTGTACCA
GCAAGAACTGTCTTTGGAGTAACAACTGTGCTCACCATGACAACATTGAGCATCAGTGCC
AGAAACTCCCTCCCTAAGGTGGCTTATGCAACAGCTATGGATTGGTTTATTGCCGTGTGC
TATGCCTTTGTGTTCTCAGCTCTGATTGAGTTTGCCACAGTAAACTATTTCACTAAGAGA
GGTTATGCATGGGATGGCAAAAGTGTGGTTCCAGAAAAGCCAAAGAAAGTAAAGGATCCT
CTTATTAAGAAAAACAACACTTACGCTCCAACAGCAACCAGCTACACCCCTAATTTGGCC
AGGGGCGACCCGGGCTTAGCCACCATTGCTAAAAGTGCAACCATAGAACCTAAAGAGGTC
AAGCCCGAAACAAAACCACCAGAACCCAAGAAAACCTTTAACAGTGTCAGCAAAATTGAC
CGACTGTCAAGAATAGCCTTCCCGCTGCTATTTGGAATCTTTAACTTAGTCTACTGGGCT
ACGTATTTAAACAGAGAGCCTCAGCTAAAAGCCCCCACACCACATCAATAG

# Drug_Target_1_General_Function:
Involved in GABA-A receptor activity

# Drug_Target_1_General_References:
11992121	Cossette P, Liu L, Brisebois K, Dong H, Lortie A, Vanasse M, Saint-Hilaire JM, Carmant L, Verner A, Lu WY, Wang YT, Rouleau GA: Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat Genet. 2002 Jun;31(2):184-9. Epub 2002 May 6.
2465923	Schofield PR, Pritchett DB, Sontheimer H, Kettenmann H, Seeburg PH: Sequence and expression of human GABAA receptor alpha 1 and beta 1 subunits. FEBS Lett. 1989 Feb 27;244(2):361-4.
2847710	Garrett KM, Duman RS, Saito N, Blume AJ, Vitek MP, Tallman JF: Isolation of a cDNA clone for the alpha subunit of the human GABA-A receptor. Biochem Biophys Res Commun. 1988 Oct 31;156(2):1039-45.

# Drug_Target_1_HGNC_ID:
HGNC:4075

# Drug_Target_1_HPRD_ID:
00662

# Drug_Target_1_ID:
872

# Drug_Target_1_Locus:
5q34-q35

# Drug_Target_1_Molecular_Weight:
51802

# Drug_Target_1_Name:
Gamma-aminobutyric-acid receptor subunit alpha-1

# Drug_Target_1_Number_of_Residues:
456

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02931	Neur_chan_LBD
PF02932	Neur_chan_memb

# Drug_Target_1_Protein_Sequence:
>Gamma-aminobutyric-acid receptor subunit alpha-1 precursor
MRKSPGLSDCLWAWILLLSTLTGRSYGQPSLQDELKDNTTVFTRILDRLLDGYDNRLRPG
LGERVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLMASK
IWTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHAC
PLKFGSYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSGIVQSSTGEYVVM
TTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISA
RNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGKSVVPEKPKKVKDP
LIKKNNTYAPTATSYTPNLARGDPGLATIAKSATIEPKEVKPETKPPEPKKTFNSVSKID
RLSRIAFPLLFGIFNLVYWATYLNREPQLKAPTPHQ

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-27

# Drug_Target_1_Specific_Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel

# Drug_Target_1_SwissProt_ID:
P14867

# Drug_Target_1_SwissProt_Name:
GBRA1_HUMAN

# Drug_Target_1_Synonyms:
Gamma-aminobutyric-acid receptor subunit alpha-1 precursor

# Drug_Target_1_Theoretical_pI:
9.61

# Drug_Target_1_Transmembrane_Regions:
252-273
279-300
313-334
422-443

#END_DRUGCARD DB01341
